TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05150626
Drug: DBPR108 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: DBPR108, tablets, oral
Study: NCT06171061
Drug: Yangxinshi tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to basic medication, the experimental group will be given Yangxinshi (three tablets each time, three times a day);The treatment period is 24 weeks.
Study: NCT04749914
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT04971577
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night
Study: NCT06676280
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin intensity is defined as 2018 Cholesterol Clinical Practice Guidelines.
Study: NCT06676280
Drug: Guideline-directed statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: as 2018 Cholesterol Clinical Practice Guidelines.
Study: NCT06037564
Drug: DOR/DTG/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 100 mg (Pifeltro®) will be administered once daily in combination with co-formulated dolutegravir/lamivudine 50/300 mg (Dovato®) for a duration of 48 weeks.
Study: NCT06715319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day (QD) by mouth (PO)
Study: NCT06717204
Drug: Prescription Drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment only
Study: NCT05431595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by Vein (IV)
Study: NCT06362005
Drug: Tacrollimus Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT
Study: NCT05980598
Drug: TransCon TLR7/8 Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLR7/8 agonist prodrug
Study: NCT05980598
Drug: TransCon IL-2 β/γ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained systemic release of IL-2 β/γ with selective receptor binding that may stimulate the immune system to kill cancer cells
Study: NCT06225115
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, oral tablet
Study: NCT04893863
Drug: Standard dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
Study: NCT04893863
Drug: PluroGel
Normalized name: PLUROGEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
Study: NCT04868292
Drug: SPR206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 100 mg SPR206 intravenous doses administered every 8 hours
Study: NCT04971928
Drug: GSK3228836
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3228836 will be administered
Study: NCT06102395
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W
Study: NCT04844125
Drug: SHR-1209 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1209 Placebo
Study: NCT05003453
Drug: 1.5% Palmitoylethanolamide (PEA) sold as Levagen+
Approvals — FDA: no, EMA: no, PMDA: no
Description: A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
Study: NCT05003453
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
Study: NCT05013554
Drug: SAR443216 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Powder for solution; Route of administration: IV infusion
Study: NCT05013554
Drug: SAR443216 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Powder for solution; Route of administration: SC injection
Study: NCT06488755
Drug: SIM0718 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: injection Specification: 300mg/2ml/bottle Dosage: A loading dose of 600 mg is injected subcutaneously on day 1, followed by 300 mg SIM0718 subcutaneously every two weeks.~Duration of medication: 52 weeks
Study: NCT06488755
Drug: SIM0718 injection of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: injection Specification: 2ml/bottle Dosage: 4ml subcutaneously on day 1, followed by 2ml of placebo subcutaneously every two weeks.~Duration of medication: 52 weeks
Study: NCT06415487
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lymphodepleting agent
Study: NCT06415487
Drug: ACE2016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic gamma delta T (gdT) cell therapy
Study: NCT06453577
Drug: Recompensation (guideline directed medical therapy)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recompensation mainly achieved by intravenous diuretics and/or vasodilators but no requirement for positive inotropic drugs such as catecholamines or levosimendan.
Study: NCT04206761
Drug: QVM149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVM149 is an investigational drug consisting of 150μg indacaterol acetate, 50μg glycopyrronium bromide and 160μg mometasone furoate. The drug is delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication
Study: NCT06629389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.
Study: NCT06718751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO administration of placebo tablet
Study: NCT06701721
Drug: THN391 MAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Route of administration- IVT injection
Study: NCT05188638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile isotonic saline
Study: NCT06102655
Drug: Jiajian Guishen Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiajian Guishen Formulation is a formulation of Traditional Chinese Medicine.POI patients will be treat with Jiajian Guishen Formulation for three menstrual cycles; their blood samples are collected before and after treatment.No drug will be used in control group, and their blood samples are collected when join the experiment.
Study: NCT05710887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Study: NCT05961098
Drug: RBD1016
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBD1016 with NAs background treatment will be explored.
Study: NCT05889286
Drug: [F-18]MHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following intravenous injection of 10 ± 2 mCi (370 ± 74 MBq) \[F-18\]MHF as a bolus, dynamic PET imaging of the lower limbs will be acquired for approximately 90 minutes. The acquired images will be processed. The uptake pattern of \[F-18\]MHF around infected orthopedic knee implant will be determined and compared with its uptake pattern around non-infected knee implants.
Study: NCT06462313
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine was titrated to maintain a mean arterial pressure at 65mmHg or more in both groups.
Study: NCT04662164
Drug: hepalatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 different dosage will be given sequentially to T2D patients
Study: NCT04260477
Drug: 6EH³R³Z
Approvals — FDA: no, EMA: no, PMDA: no
Description: A triple dose is defined as the triple of the routine dose used for a specific WHO weight band. Hence, the mg/kg within a weigh-band varies, as is the case in routine practice.~Dosing takings into consideration the fixed dose combination (FDC) tablets (one tablet: 150 mg R + 75 mg H + 400 mg Z + 275mg E). Dosage relies on tables with dosage by weight-bands used by WHO for the Cat. 1 regimen. The dosage used for the intensive phase of the Cat. 1 regimen applies for the whole treatment duration. A double dose of H and R is added to the recommended normal dose for adults (WHO,2003)
Study: NCT04660760
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05690425
Drug: BC3402 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive BC3402 as a single agent via intravenous infusion once every 3-weeks (Q3W),the dose of BC3402 was calculated according to the dose group and body weight of the subjects.
Study: NCT05233124
Drug: Acetylsalicylic acid 100mg
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 100mg
Study: NCT04887532
Drug: HR19042 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: phase 1 :8mg; phase 2:12mg; phase 3:16mg
Study: NCT04141319
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30ml of local infiltration solution containing 60mg ropivacaine
Study: NCT04141319
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30ml of local infiltration solution containing 0.1mg epinephrine
Study: NCT05958589
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the day of operation all patients will recieve midazolam 0.5 mg/kg (maximum dose 15 mg) orally. Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle relaxant rocuronium - bromide (0.6-1 mg/kg). The airway will be obtained by placing a laryngeal mask (I-gel®).
Study: NCT06644040
Drug: TeriQ Patch
Normalized name: Teril CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive two single doses of either of the TeriQ patch (Strength- 28.2 µg, 56.5 µg, and 113.0 µg) approximately 1 week apart.~Route of administration- Dermal patch
Study: NCT06644040
Drug: Teribone Inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection
Study: NCT06644040
Drug: Forteo Inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants may receive either one single dose Teribone Inj. or Forteo Inj. following TeriQ patch.~Route of administration: Sub-cutaneous Injection
Study: NCT05160545
Drug: GNC-035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT06158022
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT05942716
Drug: Administration of a PET radiotracer
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: A highly selective 5-HT2A receptor ligand (\[18F\]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine.~Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic.
Study: NCT04516603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no active component
Study: NCT06315309
Drug: ATG Combined with Tacrolimus and Mini Methotrexate
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day -7, subjects will be admitted to the hospital and receive a dose of prednisone at 1 mg/kg (ATG premedication). Subjects will receive a steroid injection 3 hours before every ATG infusion. On day -6, subjects will receive a small dose of ATG as an IV infusion. ATG will be repeated on days -5,-4 and -1. Routine transplant chemotherapy agent fludarabine will be given on days -6 to -2 as daily IV infusions. Busulfan, a routine transplant chemotherapy will be given on days -5 to -2 as IV infusion. Subjects with lymphoblastic leukemia will receive an alternative regimen of cyclophosphamide, a routine chemotherapy on days -6 and -5, followed by total body radiation on days -3 to -1. Tacrolimus (standard immune suppression agent) starts on day -3 as continuous IV infusion and switched to oral after engraftment. Methotrexate a standard immune suppression medication which is given IV on day +1,+3,+6, and +11 post-transplant. Blood draws on days -4,-1,+3,+7,+14 to measure ATG levels.
Study: NCT05838742
Drug: GSK3858279
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3858279 will be administered.
Study: NCT05838742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT05086393
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive Duloxetine or a placebo.
Study: NCT05261711
Drug: AB1
Normalized name: Hb 19(AB1), Ala-glu
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks
Study: NCT06163326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsule once daily
Study: NCT04678401
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously with Mesna on day -8 and day- 7 prior to hematopoietic stem cell transplant (HSCT)
Study: NCT05196308
Drug: Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator.
Study: NCT05196308
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator.
Study: NCT04886050
Drug: LC350189 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive an LC350189 Tablet as single dose on Day 1 or Day 5
Study: NCT04886050
Drug: LC350189 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive an LC350189 Capsule as single dose on Day 1 or Day 5
Study: NCT06680921
Drug: SIM0270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT05638828
Drug: RD14-01 Cell injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: RD14-01 Cell injection
Study: NCT04826237
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose to be taken with methylprednisolone
Study: NCT04826237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule the same as for statins but without statin
Study: NCT00704925
Drug: 3, 4 DAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
Study: NCT05079360
Drug: Sabizabulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32mg each day by mouth
Study: NCT05189210
Drug: GV1001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline
Study: NCT05189210
Drug: GV1001 0.56mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized peptide from hTERT
Study: NCT05189210
Drug: GV1001 1.12mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized peptide from hTERT
Study: NCT05187793
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment including:~* Baricitinib, 4 mg, film coated tablets~* Favipiravir, 200 mg, film coated tablets~* Dexamethasone IV or IM OR Methylprednisolone IV
Study: NCT04562116
Drug: CYP 450 Substrates
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP substrates (Caffeine, Warfarin Sodium, Midazolam, Omeprazole, and Metoprolol Tartrate) will administered orally at Week 0 (Day 1) and Week 10 as per the commercially available prescribing information.
Study: NCT04242147
Drug: KD033 (SAR445710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)
Study: NCT05069649
Drug: Ergoferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use.
Study: NCT05069649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use.
Study: NCT05884372
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the same as arm descriptions.
Study: NCT05419856
Drug: 4P-004
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intraarticular administration in the knee joint
Study: NCT05419856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intraarticular administration in the knee joint
Study: NCT05539651
Drug: RBD5044
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously Administered RBD5044 in Healthy Subjects
Study: NCT05539651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously Administered Placebo in Healthy Subjects
Study: NCT05945888
Drug: Placebo matching BI 3000202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 3000202
Study: NCT00002219
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05635227
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule identical to capsule containing olanzapine
Study: NCT06135584
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese patent medicine or hypoglycemic drugs other than pioglitazone metformin tablets, pioglitazone, metformin, GLP1
Study: NCT01245725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be dosed as an i.v. bolus followed by an i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive placebo on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion.
Study: NCT05753462
Drug: Phase 1, SQY51
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQY51 is administered by intravenous infusion.
Study: NCT05753462
Drug: Phase 2a, SQY51 (cohort 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQY51 is administered by intravenous infusion at dose 1
Study: NCT05753462
Drug: Phase 2a, SQY51 (cohort 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQY51 is administered by intravenous infusion at dose 2.
Study: NCT05753462
Drug: Phase 2a, SQY51 (cohort 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQY51 is administered by intravenous infusion at dose 3.
Study: NCT05324995
Drug: Multimodal Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Multimodal Drug group received morphine, epinephrine, and ketorolac (n=48), The epinephrine group (placebo group) (n=49) received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary,and the celecoxib group(control group)(n=49) recieved 400mg celecoxib orally
Study: NCT05324995
Drug: epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary
Study: NCT05324995
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The third group administered celecoxib (200 mg) orally immediately before the surgery
Study: NCT05195112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT06645886
Drug: KQB198
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral KQB198
Study: NCT05779657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes
Study: NCT06360419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, taken once daily
Study: NCT04973137
Drug: Standard of Care Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD)) according to the institutional standard of care